Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Adam

Gastroenterology North Chesterfield, VA Medical Doctor

NPI 1275894792 CMS profile 4220131

223 Wadsworth Dr, North Chesterfield, VA 23236

Open in the dashboard

General payments

$9,116

475 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Adam of North Chesterfield, VA is reported in the CMS Open Payments database as having received $9,116 across 475 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,480 79
2024 General $2,062 92
2023 General $1,741 80
2022 General $1,548 94
2021 General $1,349 80
2020 General $232 11
2019 General $703 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Adam
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Jason Adam were reported at $1,480. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Jason Adam Gastroenterology median Middle half National median
2019 $703 $417 $126–$1,100 $163
2020 $232 $224 $74–$624 $114
2021 $1,349 $352 $106–$1,054 $132
2022 $1,548 $448 $129–$1,270 $149
2023 $1,741 $533 $150–$1,390 $160
2024 $2,062 $605 $160–$1,606 $164
2025 $1,480 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,903 202 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,079 70 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $881 59 payments
  4. Genzyme Corporation $710 19 payments
  5. Pfizer Inc. $602 35 payments
  6. Janssen Biotech, Inc. $302 12 payments
  7. Ardelyx, Inc. $270 11 payments
  8. Celgene Corporation $216 19 payments
  9. Merck Sharp & Dohme Corporation $146 7 payments
  10. Medtronic, Inc. $113 1 payment
  11. Other $895 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,099 473 payments
  2. Education $16 2 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $1,762 82 payments
  2. SKYRIZI Immunology $1,051 52 payments
  3. HUMIRA $988 46 payments
  4. LINZESS $812 51 payments
  5. XIFAXAN $732 39 payments
  6. CREON $695 40 payments
  7. SKYRIZI Immunology $681 32 payments
  8. ENTYVIO $671 45 payments
  9. DUPIXENT $567 18 payments
  10. XELJANZ $450 24 payments
  11. Other $3,062 173 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,722

Median for Gastroenterology: 569

Drug cost

$169,000

Median for Gastroenterology: $104,976

Branded share of claims

31.2%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 75 $85,293
Zenpep Lipase/Protease/Amylase Brand 11 $18,703
Mesalamine Generic 22 $12,018
Budesonide Dr Budesonide Brand 32 $11,553
Budesonide Ec Budesonide Brand 11 $8,791
Colestipol Hcl Generic 95 $7,028
Omeprazole Generic 555 $5,119
Balsalazide Disodium Generic 17 $4,393
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 201 $2,833
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 15 $2,466

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$115,712

Medicare's payments for the services billed

Medicare patients

545

Average age 74

Services billed

1,103

302 women, 243 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Ischemic heart disease 38%
Diabetes 37%
Atrial fibrillation 28%
Chronic kidney disease 26%
Depression 25%
Heart failure 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $356
$356 — —
SKYRIZI
  • AbbVie, Inc. $304
$304 — —
DUPIXENT
  • GENZYME CORPORATION $198
$198 — —
VELSIPITY
  • PFIZER INC. $135
$135 — —
CREON
  • AbbVie, Inc. $134
$134 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

475 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record